Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by Snowballgrowthon Apr 24, 2022 9:01am
118 Views
Post# 34627080

RE:RE:RE:To clarify ...

RE:RE:RE:To clarify ...
EbbFlow88 wrote: Companies should raise money if it's on favorable terms to them. At 10$ it was clearly favorable. Not so for those who bought then but over time it may prove to still be a good investment (I believe it will, obviously). 

I think everyone will agree that the Israel investment was a mistake. No arguments there.

The funds are pretty neutral in my book. Yes, not much has come in terms of product rights but considering how much cash we have, the funds have been a great place to park excess capital. So, if that's a mistake I'll take those mistakes all day.

Even if you look at Biotoscana, it was poor timing but they couldn't have foreseen the pandemic like anyone else would have. Still, the returns are starting to show and they are still fine tuning. The margins are likely to increase from here and it's still yielding a respectable return today. 

The next year or two will show how well it plays out. Logically, there is little love for this stock, they are coming out of the pandemic which was particularly hard on GUD and expectations are rather low. I keep playing the same tune but these are the things a patient value investor looks for.

Lastly, timing is everything, people have been gushing about tech stocks for years and rightly so. Now most are down over 50% and the tables turn very quickly. You can make the same argument for PYPL, SHOP, NFLX, BABA, FB et al. and say what crappy companies. Timing will tell if they are great buys today and same with GUD. 



These 3 mistakes had been huge and many investors didn't like the fact than many hundred million had been dead money for a so long period.  The mistakes aren't only about cost opportunity and the fact than the return on capital had been so low. Even the good execution on the field can turn negative with bad capital allocation or with products price increase. 

Again I am a shareholder but  very disapointed. Even RBC changes EBITDA 2022E from $ 66 M to $ 42 M !! Think about it for a minute. From $ 66 M to  $42 M.


<< Previous
Bullboard Posts
Next >>